Publications by authors named "Ranjan Chrisanthar"

Claim this Profile
W
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.
Per E Lønning, Elisabet O Berge, Merete Bjørnslett, Laura Minsaas, Ranjan Chrisanthar

Ann Intern Med· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function.
Synnøve Yndestad, Eilin Austreid, Stian Knappskog, Ranjan Chrisanthar, Peer Kåre Lilleng

Breast Cancer Res Treat· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Stian Knappskog, Elisabet O Berge, Ranjan Chrisanthar, Stephanie Geisler, Vidar Staalesen

Mol Oncol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Stian Knappskog, Ranjan Chrisanthar, Erik Løkkevik, Gun Anker, Bjørn Østenstad

Breast Cancer Res· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Ranjan Chrisanthar, Stian Knappskog, Erik Løkkevik, Gun Anker, Bjørn Ostenstad

PLoS One· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
Stian Knappskog, Merete Bjørnslett, Line M Myklebust, Petra E A Huijts, Maaike P Vreeswijk, Ranjan Chrisanthar

Cancer Cell· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
Ranjan Chrisanthar, Stian Knappskog, Erik Løkkevik, Gun Anker, Bjørn Østenstad

PLoS One· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations and polymorphisms of the p21B transcript in breast cancer.
Stian Knappskog, Ranjan Chrisanthar, Vidar Staalesen, Anne-Lise Børresen-Dale, Inger Torhild Gram

Int J Cancer· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P21/WAF1 mutation and drug resistance to paclitaxel in locally advanced breast cancer.
Ranjan Chrisanthar, Stian Knappskog, Vidar Staalesen, Johan Richard Lillehaug, Per Eystein Lønning

Int J Cancer· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer.
Vidar Staalesen, Stian Knappskog, Ranjan Chrisanthar, Silje H Nordgard, Erik Løkkevik

Clin Cancer Res· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis